Evaluation of the use of cancer registry data for comparative effectiveness research

A Kumar, ZD Guss, PT Courtney, V Nalawade… - JAMA Network …, 2020 - jamanetwork.com
Importance Researchers often analyze cancer registry data to assess for differences in
survival among cancer treatments. However, the retrospective, nonrandomized design of …

Artificial intelligence-based personalized clinical decision-making for patients with localized prostate cancer: surgery versus radiotherapy

Y Liu, L Zhao, J Liu, L Wang - The Oncologist, 2024 - academic.oup.com
Background Surgery and radiotherapy are primary nonconservative treatments for prostate
cancer (PCa). However, personalizing treatment options between these treatment modalities …

Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer

AC Justice, JP Tate, F Howland, JM Gaziano… - European Urology …, 2024 - Elsevier
Background An electronic health record–based tool could improve accuracy and eliminate
bias in provider estimation of the risk of death from other causes among men with …

Development and validation of an interpretable artificial intelligence model to predict 10-year prostate cancer mortality

JE Bibault, S Hancock, MK Buyyounouski, H Bagshaw… - Cancers, 2021 - mdpi.com
Simple Summary This article presents a gradient-boosted model that can predict 10-year
prostate cancer mortality with high accuracy. The model was developed and validated on …

Treatment effect estimation under additive hazards models with high-dimensional confounding

J Hou, J Bradic, R Xu - Journal of the American Statistical …, 2023 - Taylor & Francis
Estimating treatment effects for survival outcomes in the high-dimensional setting is critical
for many biomedical applications and any application with censored observations. This …

Development and validation of a life expectancy calculator for US patients with prostate cancer

EC Chase, AK Bryant, Y Sun, WC Jackson… - BJU …, 2022 - Wiley Online Library
Objective To develop and validate an accurate, usable prediction model for other‐cause
mortality (OCM) in patients with prostate cancer diagnosed in the United States. Materials …

Validity of claims data for identifying cancer incidence in the Japan public health center‐based prospective study for the next generation

H Ihira, A Goto, K Yamagishi, H Iso… - … and Drug Safety, 2022 - Wiley Online Library
Purpose This study determined the validity of claims‐based definitions for identifying the
incidence of total and site‐specific cancers in a population‐based cohort study. Methods …

Using health insurance claims data to assess long‐term disease progression in a prostate cancer cohort

S Khan, S Vohra, L Farnan, SNC Elmore… - The …, 2022 - Wiley Online Library
Background Long‐term population‐based cohort studies of men diagnosed with prostate
cancer are limited. However, adverse outcomes can occur many years after treatment …

Inference under fine-gray competing risks model with high-dimensional covariates

J Hou, J Bradic, R Xu - 2019 - projecteuclid.org
The purpose of this paper is to construct confidence intervals for the regression coefficients
in the Fine-Gray model for competing risks data with random censoring, where the number …

[책][B] Survival analysis and causal inference: from marginal structural cox to additive hazards model and beyond

D Rava - 2021 - search.proquest.com
In chapter 1 we study explained variation under the additive hazards regression model for
right-censored data. We consider different approaches for develo** such a measure, and …